Guillain-Barré Syndrome following Treatment with Sunitinib Malate
Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea,...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2014/712040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850167549127294976 |
|---|---|
| author | Ziad Kanaan Zain Kulairi Mirela Titianu Sandip Saha Sarwan Kumar |
| author_facet | Ziad Kanaan Zain Kulairi Mirela Titianu Sandip Saha Sarwan Kumar |
| author_sort | Ziad Kanaan |
| collection | DOAJ |
| description | Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea, and mucositis. Scarce literature exists regarding the rare but often serious toxicities of sunitinib. Autoimmune and neurological side effects have been linked to sunitinib’s inhibition of VEGF receptors with a corresponding increase in VEGF levels, which is associated with development of different neuropathies. We hereby report an interesting case of Guillain-Barré syndrome in a middle-aged patient with metastatic renal cell carcinoma following sunitinib treatment. |
| format | Article |
| id | doaj-art-e6edcec96dc0432483b73d71b2b8a6fc |
| institution | OA Journals |
| issn | 2090-6706 2090-6714 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Oncological Medicine |
| spelling | doaj-art-e6edcec96dc0432483b73d71b2b8a6fc2025-08-20T02:21:10ZengWileyCase Reports in Oncological Medicine2090-67062090-67142014-01-01201410.1155/2014/712040712040Guillain-Barré Syndrome following Treatment with Sunitinib MalateZiad Kanaan0Zain Kulairi1Mirela Titianu2Sandip Saha3Sarwan Kumar4Department of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USADepartment of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USADepartment of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USADepartment of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USADepartment of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USASunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor (TKI) used for the treatment of metastatic renal cell carcinoma and imatinib (Gleevec)—resistant gastrointestinal stromal tumor (GIST) with few reported side effects including asthenia, myelosuppression, diarrhea, and mucositis. Scarce literature exists regarding the rare but often serious toxicities of sunitinib. Autoimmune and neurological side effects have been linked to sunitinib’s inhibition of VEGF receptors with a corresponding increase in VEGF levels, which is associated with development of different neuropathies. We hereby report an interesting case of Guillain-Barré syndrome in a middle-aged patient with metastatic renal cell carcinoma following sunitinib treatment.http://dx.doi.org/10.1155/2014/712040 |
| spellingShingle | Ziad Kanaan Zain Kulairi Mirela Titianu Sandip Saha Sarwan Kumar Guillain-Barré Syndrome following Treatment with Sunitinib Malate Case Reports in Oncological Medicine |
| title | Guillain-Barré Syndrome following Treatment with Sunitinib Malate |
| title_full | Guillain-Barré Syndrome following Treatment with Sunitinib Malate |
| title_fullStr | Guillain-Barré Syndrome following Treatment with Sunitinib Malate |
| title_full_unstemmed | Guillain-Barré Syndrome following Treatment with Sunitinib Malate |
| title_short | Guillain-Barré Syndrome following Treatment with Sunitinib Malate |
| title_sort | guillain barre syndrome following treatment with sunitinib malate |
| url | http://dx.doi.org/10.1155/2014/712040 |
| work_keys_str_mv | AT ziadkanaan guillainbarresyndromefollowingtreatmentwithsunitinibmalate AT zainkulairi guillainbarresyndromefollowingtreatmentwithsunitinibmalate AT mirelatitianu guillainbarresyndromefollowingtreatmentwithsunitinibmalate AT sandipsaha guillainbarresyndromefollowingtreatmentwithsunitinibmalate AT sarwankumar guillainbarresyndromefollowingtreatmentwithsunitinibmalate |